Other ADCs, such as SHR-A1403 and MYTX-011, have been developed and demonstrated enhanced efficacy and safety compared to existing small-molecule inhibitors or monoclonal antibodies targeting MET-overexpressing cancers [148,149]. This evidence concerns the gene MET and cancer.